==== Front Ann Saudi MedAnn Saudi MedAnnals of Saudi Medicine0256-49470975-4466King Faisal Specialist Hospital and Research Centre 2356300610.5144/0256-4947.2013.162asm-2-162Original ArticlePhyllodes tumor of the breast: a retrospective study of the impact of histopathological factors in local recurrence and distant metastasis Sawalhi Samer aAl-Shatti Marwa b a Department of Surgery-College of Medicine, Taibah University, Al Madinah, Saudi Arabia b Department of Pathology, King Hussein Cancer Center, Amman, JordanCorrespondence: Dr. Samer Sawalhi, Surgery, Taibah University, Al-Madinah 30001 Saudi Arabia, drsawalhi@yahoo.comMar-Apr 2013 33 2 162 168 Copyright © 2013, Annals of Saudi Medicine2013This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.BACKGROUND AND OBJECTIVES The challenging issue for the breast surgeons is local recurrence of phyllodes tumor. The histological criteria to predict local recurrence has been a controversial issue. The objective of this study was to determine pathological parameters and surgical margins that influence outcome of local recurrence and distant metastasis in phyllodes tumor (PT). DESIGN AND SETTING Retrospective review between January 2003 to August 2008 at King Hussein Cancer Center-Jordan. PATIENTS AND METHODS Forty-two female patients diagnosed as having PT were classified to benign, borderline and malignant. The medical records were reviewed in relation to the surgical management, recurrence, follow-up, the histological features of the tumor and grading of tumours based on the following histological parameters: mitotic count, stromal cellularity, stromal overgrowth, cellular pleomorphism, nuclear grade, tumor necrosis, tumor margin, and surgical margin status. All patients underwent wide local excision of the tumor or mastectomy. RESULTS Forty-two patients with PT (16 benign, 9 borderline, 17 malignant PT) were followed up for 30 months. The mean age was 39.8 years, and the average tumor size was 6.6 cm. The recurrence rate of PT in our study was 21% at a mean time of 11 months. Nine patients had local recurrence; 2 benign, 6 malignant and 1 borderline. Cellular pleomorphism had correlation with recurrence rate (P=.045). We had six patients (14%) with distant metastasis. All had malignant PT. Metastasis in PT has a relationship with histological grade (P=.02). CONCLUSIONS We conclude that patients with moderate and severe cellular pleomorphism had higher local recurrence, while metastatic PT occur more in patients with high nuclear grade. ==== Body Mammary phyllodes tumors (PTs) are uncommon biphasic, fibroepithelial neoplasms composed of epithelium and a spindle-cell stroma that accounts for 0.3–1% of all primary breast tumors.1 The behavior of PTs in all forms (benign, borderline, and malignant) is unpredictable2 and the distinction between benign, borderline and malignant tumors is often difficult and does not always reflect the clinical behavior. Triple assessment by clinical, radiological and histological examination forms the fundamental basis for the evaluation of PTs. Treatment could be either by wide excision or mastectomy provided that clear histological margins are achieved. Wide local excision with at least 1 cm clear margin is currently the standard of treatment of PT in most institutions.3–5 To date, the local recurrence rate in PT is approximately 15%.6–8 Local recurrence usually occurs within the first few years following surgery, especially if it was with incomplete excision.3 Some authors argue that histological criteria can be used to predict the likelihood of local recurrence.9 Local recurrence can usually be controlled by another surgery including wider excision or even mastectomy.2 It is unclear whether malignant PTs are associated with high recurrence rate10,11 or whether the positive margins are responsible for this recurrence.2,5 Approximately 20% of patients with malignant PTs develop distant metastasis.4–6,12 Most distant metastasis develops without evidence of local recurrence, while several studies have shown that local recurrence is a strong predictor of metastatic spread.13–15 The most common sites for distant metastasis are the lung, bone, limbs and rarely to the abdominal viscera.16 The objective of this study was to determine pathological parameters and surgical margins that influence outcome of local recurrence and distant metastasis in PT patients managed at King Hussein Cancer Centre. PATIENTS AND METHODS This was a retrospective study involving 42 consecutive patients with PT. The database from department of surgery and anatomical pathology at King Hussein Cancer Center, Amman, Jordan was utilised to identify 42 patients diagnosed with PT by histopathology from January 2003 to August 2008. The study was conducted with prior approval of the institutional review board. Each individual case history was reviewed from hospital records to obtain demographic and clinical data which are illustrated in Table 1. The tumors were classified into benign, borderline and malignant according to the WHO classification.17 The medical records were reviewed according to the surgical management, the histological features of the tumor as well as recurrence and follow-up. Triple assessment was obtained by clinical, ultrasonography and/or mammography and true-cut biopsy. All patients underwent wide local excision of the tumor or mastectomy based on the breast-to- tumor ratio, grade of the tumor, margin status and recurrence. All of the original haematoxylin and eosin slides were prepared using formalin fixed paraffin embedded. Routine haematoxylin and eosin staining procedure was done and reviewed blindly by a single pathologist using 3 μm thick paraffin sections. Cases with no archived paraffin blocks were excluded. The pathological diagnosis and grading of tumors were reviewed based on the following histological parameter: mitotic count (per 10 high power field [HPF]) using 40× lens Olympus BX 41 microscope, stromal cellularity (low-intermediate-high). The grades of stromal cellulariy were selected based on the a) amount of the cells. Typically, the stroma shows a variable degree of stromal cellularity, with some areas being hypocellular and other areas being hypercellular, b)the stromal cells may show variable nuclear pleomorphism, ranging from a bland appearance to frankly sarcomatous morphology, c) mitotic activity, d) stromal overgrowth (present or absent; defined as at least one 40× field of stroma without epithelium),18 scromal nuclear atypia/cellular pleomorphism (mild-moderate-severe), nuclear grade (low grade: well differentiated and mitotic figure 2-5/HPF), (intermediate grade: moderate differentiated and mitotic figure 5–10/HPF), (high grade: mitotic figure >10/HPF with bizarre looking cells and hyperchromatism in the nucleus with irregular nuclear borders) and other features including tumor necrosis, tumor margin (infiltrative versus pushing with compression adjacent tissues), surgical margin status (positive or negative) <1 mm versus >1 mm. We considered a microscopic safety margin of 1 mm as a cutpoint. Typically a benign PT has low stromal cellularity, low mitotic count (less than 2–5/10HPF), around margin, abscence of stromal cell atypia or nuclear pleomorphism, abscence of stromal overgrowth, and abscence of necrosis or malignant heterologous elements. On the other hand, malignant PT shows stromal hypercellularity, significant stromal cell atypia or nuclear pleomorphism, high mitotic count(>10/HPF), stromal overgrowth, an infiltrative margin and necrosis or malignant heterologous element. Many patients do not possess all the features for malignancy, and are labelled as having borderline PT. Following review of the 42 patients diagnosed with PT, 16 were classified as benign, 9 as borderline and 17 as malignant. These pathological variables were assessed as predictors of local recurrence and metastases in addition to other parameters such as tumor size and surgical margins. Comparisons of categorical variables such as stromal cellularity, stromal proliferation, nuclear grade, cellular pleomorphism and tumor necrosis were performed using the chi-square test. A comparison of continuous variables, such as mitotic figures was carried out using Kruskal-Wallis test. All tests were carried out using SAS software (version 9.1). A P value of less than .05 was considered significant. RESULTS Forty-two women were diagnosed with PT between January 2003 to August 2008 with ages ranging between 12–59 years (mean=39.8 years, median=43.5 years). Thirty-seven (88%) were premenopausal while the remaining 5 (12%) were postmenopausal. Both breasts were almost equally involved with PT in our study, but the upper outer quadrant was the most common site (43% in comparison to other sites in the breast). A family history of breast cancer was reported only in 5 patients (12%). The tumor size ranged between 2 to 29 cms (mean=6.68 cm, median 5.0 cm) with median duration of 6 months. The mean follow-up period was 30 months. Mitotic figure, stromal cellularity, stromal proliferation, nuclear grade, cellular pleomorphism and tumor necrosis were compared among the pathological types. After analysis, there were significant differences between the pathological types; 16 benign (38%), 9 borderline (21%) and 17 malignant PT (40%) with (P<.05) in most variables (Table 1). All 42 cases were treated by surgical resection either with wide local excision or mastectomy with adequate safety margin. The recurrence rate for all PT in our study was 21%. The duration between the date of surgery and local recurrence was about 11 months. Nine patients had local recurrence; 2 benign, 6 patients had malignant type and 1 borderline (Table 2). After studying these recurrent cases with all pathological parameters including margin status and the size we conclude that only cellular pleomorphism has correlation with recurrence. Patients with moderate and severe cellular pleomorphism had higher recurrence rate (P=.045) (Table 2). We consider a microscopic safety margin of 1 mm as a cutpoint, so even a negative margin could harbor a risk of recurrence that reached up to 14.3% in our study. It was found that 6 cases (14%) metastasized, and all were malignant. They were detected by regular follow-up in high-risk patients, which is predetermined by tumor biology6 using a bone scan, chest and abdomen computerized tomography scan. The duration between the date of sur gery and metastatic date was a mean of 15.9 months. Three cases metastasized to the lung only, one to the bone and the other two cases metastasized to more than two organs such as bone, lung, thigh and intestine. Metastasis in PT had an association with histological grade, so that high-grade PTs had metastasis (Table 3). DISCUSSION The clinical behavior of PT is poorly understood. Fibroadenoma is a benign solid breast tumor composed of fibroglandular tissue in young women.19 Fibroadenoma and PT differ in their biological behavior; the latter has a propensity to recur locally and is able to metastasize3 and therefore, the management of PT is individually based.3 Triple assessment is the standard and core biopsy employed with sensitivity reached up to 70%, while false negative results reached up to 30% in our study. Gatta G et al confirmed that an ultrasound-guided core needle biopsy is highly sensitive and specific to differentiate between fibroadenoma and PT.20 Until the late 1970s, mastectomy was the standard surgical treatment for all PT, irrespective of tumor size or histological type.21 Today more conservative surgical options have been adopted to assess which operation is suitable for a PT patient. There is no definite agreement regarding the appropriate surgical procedure, since PTs are rarely multifocal. In literature review, wide local excision is currently being suggested to be an appropriate primary surgical procedure for all histological types of PTs12,22 with minimal 1 cm safe margins,4,5,12,23 taking advantage of breast conserving surgery where feasible. For borderline, malignant PT, greater than 10 cm in size,22 or in cases of local tumor recurrence, mastectomy and immediate breast reconstruction may become the preferred option,24 depending on the breast to tumor ratio. It has been suggested that mastectomy is no longer required, even for malignant PT, provided adequate resection margins can be achieved.25 Local recurrence can usually be controlled by further wide excision26 and mastectomy is not invariably required. Re-excision is recommended in cases with a positive surgical margin, stromal overgrowth and malignancy.27 In few instances, more radical surgery will be required for optimal control. Axillary lymph node dissection was unnecessary because lymph node metastasis to the axilla reached up to 14% in our series. There is no consensus on specific grading system that predicts the behavior of PTs and even benign PT may metastasize.1 The expression of many biological markers has been explored to discriminate between different grades of PTs and to predict their behavior. Recently Puay Hoon Tan et al8 established a predicted monogram based on three histological criteria (stromal atypia, mitosis, overgrowth) and surgical margin (AMOS criteria) to calculate recurrence-free survival in women diagnosed with PT. The recurrence rate in our study was 21% at an average time of 11 months, which matches the WHO recurrence rate.1 A local recurrence rate of 10% to 40% has been reported making average of 15%.6,8,28 A follow-up period of 30 months was used because the median time for recurrence is less than 24 months in almost all of the studies. 5,12,13,29,30 Margins affect the choice of the procedure, so borderline and malignant tumor types should not be considered an absolute indication for mastectomy. De Roos et al29 noticed that patients with recurrence have margin involvement on histological examination, but not all patients with the margin involvement developed recurrence. Achievement of clear surgical margins in management of malignant PT is important and recommended to be at least 1 cm;5,12,31,32 therefore, there is some evidence that excision with a negative margin will result in decreased recurrence rates8,14,28 even though this alone offers no guarantees. In contrast, other studies failed to establish any relationship between margin involvement and local recurrence of PT.2,3 Some previous studies suggest that tumor size is not necessarily associated with local recurrence risk.12,33–35 The relationship between the size of PT and local recurrence is controversial. In contrast, others found that larger tumors were more likely to develop a local recurrence. 5,13,14,29 Kaprisi et al concluded that tumor size and surgical margins found to be the principal determinant of local recurrence and distant metastasis.12 In our study, tumor size and surgical margins were not correlated with local recurrence as shown in Table 2. Different studies have considered that stromal overgrowth, 36–38 infiltrating margins,38 high mitotic rate,39 and degree of stromal atypia40,41 are important predictors of recurrence and/or prognosis, while others have disagreed with these findings.13,42 tumor size, degree of mitotic activity and stromal atypia have been described as predisposing factors for the development of distant metastasis.12,29,34,36 In our study, metastasis was related to the histological grade (Table 3) and local recurrence was not found to be a predictive sign of distant metastases. However, both borderline and malignant PTs are known to metastasize, whereas, not all PTs classified as malignant will metastasize.43 The role of chemotherapy, radiotherapy and hormonal manipulation in both the adjuvant and palliative settings remain to be defined. The role of adjuvant treatment is unclear and has not been the subject of large randomized controlled trials.6,33,43 Although Barth et al concluded that margin-negative resection combined with adjuvant radiotherapy is very effective therapy for local control of borderline and malignant PT.7 To sum up, this is a single institution experience of a rare tumor, the first study to shed light on cellular pleomorphism and recurrence rate in PT. The local recurrence rate is within the range reported in previous series. We conclude that only cellular pleomorphism had a correlation with local recurrence of PT while metastatic PT had relation with histological grade. The surgical management needs to be tailored to the clinical situation with more aggressive management reserved for higher grade or recurrent tumors. If satisfactory cosmosis cannot be obtained, then mastectomy is mandatory. Current studies have found that new genetic mutation and intratumoral genetic heterogeneity can develop within the same tumor.44 These mutations could be the explanation of malignant behavior or recurrence of PT; for example, loss of expression of (P16INK4a) gene was found frequently in malignant PT,44 also activation mutations in and overexpression of epidermal growth factor receptor gene (egfr) are associated with progression in the grade of breast PT.45 Up to now, only correlations between expression of P53, Ki 67,c-Kit, PDGF, VEGF and CD10 with tumor grade46–50 have been described. We recommend more prospective studies to determine the specific triggers that responsible for aggressive behavior of PT, and to study mutations in (egfr) gene to be considered as a prognostic indicator for metastatic PT. Table 1 Distinction between phyllodes subtypes based on histopathological criteria (n=42). Pathological criteria Total Benign (B) Borderline (BR) Malignant (M) Chi-square/Kruskal-Wallis P Mitotic figures 0.000 Mean (Min, Max) 1.97 (0.5) 12.9 (2.30) 23.9 (4.78) Stromal cellularity Low 6 6 (37.5%) Intermediate 20 10 (62.5%) 7 (77.8%) 3 (17.6%) .000 High 16 2 (22.2%) 14(82.4%) Stromal proliferation ? 1 1 ( 5.9%) Present 19 4 (25.0%) 3 (33.3%) 12 (70.6%) .037 Absent 22 12 (75.0%) 6 (66.7%) 4 (23.5%) Nuclear grade Low 15 14 (87.5%) 1 (5.9%) Intermediate 16 2 (12.5%) 8 (88.9%) 6 (35.3%) .000 High 11 1 (11.1%) 10 (58.8%) Cellular pleomprphis Mild 20 13 (81.3%) 5 (55.6%) 2 (11.8%) Moderate 13 3 (18.8%) 3 (33.3%) 7 (41.2%) .001 Severe 9 1 (11.1%) 8 (47.1%) Margin type ? 3 1 ( 6.3%) 2 (11.8%) Pushing 35 15 (93.8%) 9 (100%) 11 (64.7%) .082 Infiltrating 4 4 (23.5%) Tumor necrosis ? 2 2 (11.8%) Yes 11 1 ( 6.3%) 1 (11.1%) 9 (52.9%) .004 No 29 15 (93.8%) 8 (88.9%) 6 (35.3%) Margin status ? 4 1 (6.3%) 3 (17.6%) Negative 28 8 (50.0%) 9 ( 100%) 11 (64.7%) .050 Positive 10 7 (43.8%) 3 (17.6%) Positive margin ? 3 2 (28.6%) 1 (33.3%) Focal 6 4 (57.1%) 2 (66.7%) .788 Diffuse 1 1 (14.3%) ?: Unknown B: Benign PT BR: Borderline PT M: Malignant PT Table 2 Pathological review of 42 patients with PT and local recurrence (n=42). Pathological criteria Total No Recurrence (NR) Recurrence (R) Chi-Square / Kruskal-Wallis P Size ? 10 4 6 .15 10 cm 5 4 (80.0%) 1 (20.0%) 5–10 cm 11 9 (81.8%) 2 (18.2%) < 5 cm 16 16 (100%) Mitotic figures <5 18 16 (88.9%) 2 (11.1%) .137 5–10 8 7 (87.5%) 1 (12.5%) >10 16 10 (62.5%) 6 (37.5%) Pathology Diagnosis Benign 16 14 (87.5%) 2 (12.5%) .195 Borderline 9 8 (88.9%) 1 (11.1%) Malignant 17 11 (64.7%) 6 (35.3%) Stromal Cellularity Low 6 5 (83.3%) 1 (16.7%) .475 Intermediate 20 17 (85.0%) 3 (15.0%) High 16 11 (68.8%) 5 (31.3%) Stromal Proliferation ? 1 1 (100%) .094 Present 19 14 (73.7%) 5 (26.3%) Absent 22 19 (86.4%) 3 (13.6%) Nuclear grade Low 15 14 (93.3%) 1 (6.7%) .172 Intermediate 16 12 (75.0%) 4 (25.0%) High 11 7 (63.6%) 4 (36.4%) Cellular Pleomprphis Mild 20 19 (95.0%) 1 (5.0%) .045 Moderate 13 8 (61.5%) 5 (38.5%) Severe 9 6 (66.7%) 3 (33.3%) Margin type ? 3 2 (66.7%) 1 (33.3%) .276 Pushing 35 29 (82.9%) 6 (17.1%) Infiltrating 4 2 (50.0%) 2 (50.0%) Tumor necrosis ? 2 1 (50.0%) 1 (50.0%) .474 Yes 11 8 (72.7%) 3 (27.3%) No 29 24 (82.8%) 5 (17.2%) Margin status ? 4 2 (50.0%) 2 (50.0%) .199 Negative 28 24 (85.7%) 4 (14.3%) Positive 10 7 (70.0%) 3 (30.0%) Positive Margin ? 3 1 (33.3%) 2 (66.7%) .240 Focal 6 5 (83.3%) 1 (16.7%) Diffuse 1 1 (100%) Negative Margin ? 9 8 (. %) 1 (. %) .596 Size ≤1 mm 9 8 (88.9%) 1 (11.1%) Size >1 mm 10 8 (80.0%) 2 (20.0%) R: Recurrence NR: Non recurrence: Not known Table 3 Histopathological parameters in PT patients with distant metastases (n=6). Pathological criteria Grade Mitotic figure Cellular pleomorphism Low Intermediate High <5 5–10 >10 Mild Moderate Severe Total 15 16 11 18 8 16 20 13 9 No Metastasis (NM) 13 (36.1%) 16 (44.4%) 7 (19.4%) 18 (50.0%) 6 (1607%) 12 (33.3%) 18 (50.0%) 11 (30.6%) 7 (19.4%) Metastasis (M) 2 (33.3%) - 4 (66.7%) - 2 (33.3%) 4 (66.7%) 2 (33.3%) 2 (33.3%) 2 (33.3%) P value (chi-square test) .029 .072 .678 M: metastasis NM: Non metastasis ==== Refs REFERENCES 1 Tavassoli FA Devilee P World Health Organization, International Agency for Research on Cancer International Academy of pathology Pathology and Genetics of Tumours of the Breast and Female Genital Organs Lyon IARC Press 2003 2 Sotheran W Domjan J Jeffrey M Wise MH Perry PM Phyllodes tumours of the breast--a retrospective study from 1982–2000 of 50 cases in Portsmouth Ann R Coll Surg Engl 2005 87 339 44 16176692 3 Karim RZ Gerega SK Yang YH Spillane A Carmalt H Scolyer RA Lee CS Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution Breast 2009 18 165 70 19329316 4 Macdonald OK Lee CM Tward JD Chappel CD Gaffney DK Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program Cancer 2006 107 2127 33 16998937 5 Asoglu O Ugurlu MM Blanchard K Grant CS Reynolds C Cha SS Donohue JH Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors Ann Surg Oncol 2004 11 1011 7 15525831 6 Parker SJ Harries SA Phyllodes tumours Postgrad Med journal 2001 77 428 435 11423590 7 Barth RJ Jr Wells WA Mitchell SE Cole BF A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors Ann Surg Oncol 2009 16 2288 94 19424757 8 Tan PH Thike AA Tan WJ Thu MM Busmanis I Li H Chay WY Tan MH The Phyllodes Tumour Network Singapore Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins J Clin Pathol 2011 9 Kario K Maeda S Mizuno Y Makino Y Tankawa H Kitazawa S Phyllodes tumor of the breast: a clinicopathologic study of 34 cases J Surg Oncol 1990 45 46 51 2166186 10 Grimes MM Cystosarcoma phyllodes of the breast: histologic features, flow cytometric analysis, and clinical correlations Mod Pathol 1992 5 232 9 1323101 11 Mokbel K Price RK Mostafa A Wells CA Carpenter R Phyllodes tumour of the breast: a retrospective analysis of 30 cases Breast 1999 8 278 81 14965745 12 Reinfuss M Mituś J Duda K Stelmach A Ryś J Smolak K The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases Cancer 1996 77 910 6 8608483 13 Kapiris I Nasiri N A’Hern R Healy V Gui GP Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast Eur J Surg Oncol 2001 27 723 30 11735168 14 Belkacémi Y Bousquet G Marsiglia H Ray-Coquard I Magné N Malard Y Lacroix M Gutierrez C Senkus E Christie D Drumea K Lagneau E Kadish SP Scandolaro L Azria D Ozsahin M Phyllodes tumor of the breast Int J Radiat Oncol Biol Phys 2008 70 492 500 17931796 15 Pezner RD Schultheiss TE Paz IB Malignant phyllodes tumor of the breast: local control rates with surgery alone nt J Radiat Oncol Biol Phys 2008 71 710 3 16 Morcos BB Baker B Hashem SA Ileocaecal intussusception secondary to metastatic phyllodes tumour of the breast Ann R Coll Surg Engl 2010 92 W29 30 17 The World Health Organization Histological typing of breast tumors Neoplasma 1983 30 113 23 6300707 18 Tse GM Niu Y Shi HJ Phyllodes tumor of the breast: an update Breast Cancer 2010 17 29 34 19434472 19 Liu XF Zhang JX Zhou Q Chen F Shao ZM Lu C A clinical study on the resection of breast fibroadenoma using two types of incision Scand J Surg 2011 100 147 52 22108740 20 Gatta G Iaselli F Parlato V Di Grezia G Grassi R Rotondo A Differential diagnosis between fibroadenoma, giant fibroadenoma and phyllodes tumour: sonographic features and core needle biopsy Radiol Med 2011 116 905 18 21509559 21 Dyer NH Bridger JE Taylor RS Cystosarcoma phylloides Br J Surg 1966 53 450 5 4378155 22 Bhargav PR Mishra A Agarwal G Agarwal A Verma AK Mishra SK Phyllodes tumour of the breast: clinicopathological analysis of recurrent vs. non-recurrent cases Asian J Surg 2009 32 224 8 19892625 23 Joshi SC Sharma DN Bahadur AK Maurya R Kumar S Khurana N Cystosarcoma phyllodes: our institutional experience Australas Radiol 2003 47 434 7 14641198 24 Guillot E Couturaud B Reyal F Curnier A Ravinet J Laé M Bollet M Pierga JY Salmon R Fitoussi A Breast Cancer Study Group of the Institut Curie Management of phyllodes breast tumors Breast J 2011 17 129 37 21251125 25 Hart J Layfield LJ Trumbull WE Brayton D Barker WF Giuliano AE Practical aspects in the diagnosis and management of cystosarcoma phyllodes Arch Surg 1988 123 1079 83 2843145 26 Chua CL Thomas A Ng BK Cystosarcoma phyllodes: a review of surgical options Surgery 1989 105 141 7 2536964 27 Taira N Takabatake D Aogi K Ohsumi S Takashima S Nishimura R Teramoto N Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin Jpn J Clin Oncol 2007 37 730 6 17932112 28 Barth RJ Jr Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors Breast Cancer Res Treat 1999 57 291 5 10617306 29 de Roos WK Kaye P Dent DM Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast Br J Surg 1999 86 396 9 10201787 30 Abdalla HM Sakr MA Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast J Egypt Natl Canc Inst 2006 18 125 33 17496937 31 Salvadori B Cusumano F Del Bo R Delledonne V Grassi M Rovini D Saccozzi R Andreola S Clemente C Surgical treatment of phyllodes tumors of the breast Cancer 1989 15 63 2532 6 2541890 32 Zurrida S Bartoli C Galimberti V Squicciarini P Delledonne V Veronesi P Bono A de Palo G Salvadori B Which therapy for unexpected phyllode tumour of the breast? Eur J Cancer 1992 28 654 7 1317204 33 Turalba CI el-Mahdi AM Ladaga L Fatal metastatic cystosarcoma phyllodes in an adolescent female: case report and review of treatment approaches J Surg Oncol 1986 33 176 81 3022078 34 Hines JR Murad TM Beal JM Prognostic indicators in cystosarcoma phylloides Am J Surg 1987 153 276 80 3030151 35 Barrio AV Clark BD Goldberg JI Hoque LW Bernik SF Flynn LW Susnik B Giri D Polo K Patil S Van Zee KJ Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast Ann Surg Oncol 2007 14 2961 70 17562113 36 Hawkins RE Schofield JB Fisher C Wiltshaw E McKinna JA The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes Cancer 1992 69 141 7 1309302 37 el-Naggar AK Ro JY McLemore D Garnsy L DNA content and proliferative activity of cystosarcoma phyllodes of the breast. Potential prognostic significance Am J Clin Pathol 1990 93 480 5 2157332 38 Feakins RM Mulcahy HE Nickols CD Wells CA p53 expression in phyllodes tumours is associated with histological features of malignancy but does not predict outcome Histopathology 1999 35 162 9 10460662 39 Tse GM Putti TC Kung FY Scolyer RA Law BK Lau TS Lee CS Increased p53 protein expression in malignant mammary phyllodes tumors Mod Pathol 2002 15 734 40 12118111 40 Pietruszka M Barnes L Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases Cancer 1978 41 1974 83 206344 41 Norris HJ Taylor HB Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases Cancer 1967 20 2090 9 4294565 42 Contarini O Urdaneta LF Hagan W Stephenson SE Jr Cystosarcoma phylloides of the breast: a new therapeutic proposal Am Surg 1982 48 157 66 6282155 43 Hopkins ML McGowan TS Rawlings G Liu FF Fyles AW Yeoh JL Manchul L Levin W Phylloides tumor of the breast: a report of 14 cases J Surg Oncol 1994 56 108 12 8007675 44 Jones AM Mitter R Springall R Graham T Winter E Gillett C Hanby AM Tomlinson IP Sawyer EJ Phyllodes Tumour Consortium A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence J Pathol 2008 214 533 44 18288784 45 Kersting C Kuijper A Schmidt H Packeisen J Liedtke C Tidow N Gustmann C Hinrichs B Wülfing P Tio J Boecker W van Diest P Brandt B Buerger H Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression Lab Invest 2006 86 54 61 16258523 46 Feakins RM Wells CA Young KA Sheaff MT Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast Hum Pathol 2000 31 1214 22 11070114 47 Chan YJ Chen BF Chang CL Yang TL Fan CC Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast J Chin Med Assoc 2004 67 3 8 15077883 48 Chen CM Chen CJ Chang CL Shyu JS Hsieh HF Harn HJ CD34, CD117, and actin expression in phyllodes tumor of the breast J Surg Res 2000 94 84 91 11104647 49 Tse GM Lui PC Lee CS Kung FY Scolyer RA Law BK Lau TS Karim R Putti TC Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases Hum Pathol 2004 35 1053 7 15343505 50 Tse GM Putti TC Lui PC Lo AW Scolyer RA Law BK Karim R Lee CS Increased c-kit (CD117) expression in malignant mammary phyllodes tumors Mod Pathol 2004 17 827 31 15044924